ADC Therapeutics Cuts 30% of Workforce, Closes UK R&D Site Amid Strategic Shift

ADC Therapeutics is laying off 30% of its workforce and shutting down its UK research and development site, with the process expected to be completed by September 30, 20251.

The company is discontinuing several early-stage preclinical programs focused on solid tumors, including exatecan-based antibody-drug conjugates targeting Claudin-6 and ASCT21.

This restructuring follows the termination of its only clinical-stage candidate and several other development programs due to disappointing trial results and limited efficacy1.

ADC Therapeutics aims to reallocate resources toward its approved monoclonal antibody cancer drug, Zynlonta, and a preclinical program targeting prostate-specific membrane antigen1.

The company estimates total restructuring costs to be between $6 million and $7 million1.

Sources:

1. https://www.fiercebiotech.com/biotech/adc-shutters-uk-rd-site-culls-several-preclinical-programs-and-trims-workforce-30